Table 2.
LEDD and levodopa responsiveness in probable MSA subgroups
| Overall (n=43) | MSA-P (n1=22) | MSA-C (n2=21) | Test statistic | P | |
|---|---|---|---|---|---|
| Total LEDD in mg/day [Median (IQR)]$ | 300 (300) | 400 (413) | 200 (100) | 141.5 | 0.028* |
| Levodopa responsiveness@ [n (%)] | |||||
| No response | 30 (66.7) | 9 (40.9) | 21 (91.3) | 13.481 | 0.004** |
| Minimal response (1-30%) | 11 (24.4) | 10 (45.5) | 1 (4.3) | ||
| Good response (31-60%) | 0 (0) | 0 (0) | 0 (0) | ||
| Very good response (>60%) | 0 (0) | 0 (0) | 0 (0) | ||
| Initially minimal response but later no response | 1 (2.2) | 1 (4.5) | 0 (0) | ||
| Initially good response but later no response | 3 (6.7) | 2 (9.1) | 1 (4.3) |
MSA=multiple system atrophy; MSA-P=parkinsonian variant; MSA-C=cerebellar variant; LEDD=levodopa equivalent drug dose; IQR=interquartile range, $Mann-Whitney U-test, @Pearson’s Chi-square/Fisher’s exact test, *P<0.05, **P<0.01